Panel Discussion: Competing Beyond Dupixent: Leveraging Unique Mechanisms of Action & Long- Acting Drugs to Differentiate in the Next Wave of Atopic Dermatitis Therapeutics
- Positioning new mechanisms of action such as IL-31 inhibition and long-acting drugs as a potentially best-in-class alternative in moderate-to-severe atopic dermatitis
- Assessing how infrequent maintenance dosing compares with Dupixent, Ebglyss and oral JAK inhibitors, improving convenience and long-term adherence potential, to strengthen differentiation in an increasingly crowded AD market
- Understanding whether deeper and sustained responses with highly selective IL-13 blockade can redefine competitive benchmarks for efficacy, safety and patient preference, aligning clinical outcomes with payer and physician expectations, to maximise uptake and commercial value ahead of planned Phase 3 initiation in 2H 2026